ArticleBMC public health2025
Acceptance and preference for long-acting antiretrovirals among people living with HIV in China.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionLong-acting antiretroviral (LAARV) regimens have been shown to be as effective as standard daily oral antiretroviral therapy (ART) in maintaining HIV-1 suppression. China has one of the largest populations of people living with HIV (PLHIV) and provides a national free ART program with limited regimens, which currently does not include LAARV. The acceptability of LAARV among PLHIV in China remains unknown.
methodsBetween 1 June 2022 and 30 November 2022, we conducted an online survey among PLHIV in China to assess their acceptance and preference for LAARV. Acceptance was measured on a five-point scale and dichotomized into "more likely to use" (including "definitely" and "probably") and "less likely to use" (including "uncertainly", "would not" and "definitely would not"). Logistic regression was used to identify factors associated with acceptance.
resultsAmong the 2570 PLHIV who responded to the questionnaire, 67% expressed interest in LAARV. Participants currently using a single-tablet regimen (STR) showed the highest interest in LAARV (adjusted odds ratio [AOR] 1.64, 95% confidence interval [CI] 1.29-2.10). A subjective assessment of suboptimal ART adherence was also associated with greater interest (AOR 2.25, 95% CI 1.13-4.49). Preferences for LAARV modalities, in descending order, were intramuscular injection (every 1-2 months), subdermal implants (every 6-12 months), and intravenous infusion (every 1-2 weeks).
conclusionsThis study reveals a high acceptance of LAARV among PLHIV in China and identifies key potential user groups, thereby addressing a critical evidence gap regarding LAARV implementation in the country. A cost-competitive long-acting intramuscular injection ART is the most preferred LAARV option in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.